LAZARD EXPANDS ITS HEALTHCARE SERVICES TEAM WITH ADDITION OF JOHN KOSKI AND ROBERT LOWE
Rhea-AI Summary
Lazard (NYSE: LAZ) announced two senior hires: John Koski and Rob Lowe joined as Managing Directors in the Healthcare Group in New York on Feb 18, 2026.
Both join from Allen & Co. and will advise across healthcare services, strengthening Lazard's advisory capacity amid evolving policy, capital markets, and technology shifts.
Positive
- None.
Negative
- None.
News Market Reaction – LAZ
On the day this news was published, LAZ gained 0.54%, reflecting a mild positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $28M to the company's valuation, bringing the market cap to $5.22B at that time.
Data tracked by StockTitan Argus on the day of publication.
Market Reality Check
Peers on Argus
LAZ was down 1.2% while key peers MC (-3.82%), PIPR (-1.3%), SNEX (-0.73%) and PJT (-1.59%) also declined; BGC rose 1.17%. Momentum scanner only flagged RIOT (+4.51%), outside this group, indicating the move looked stock- and news-specific rather than part of a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 10 | AUM update | Positive | -0.1% | Reported January 2026 AUM of $266.95B with market and FX appreciation. |
| Jan 29 | CFO appointment | Neutral | +2.2% | Named Tracy Farr as CFO effective Feb 1, 2026, succeeding prior CFO. |
| Jan 29 | Earnings results | Positive | +2.2% | Reported Q4 and full-year 2025 results with record advisory revenue and higher AUM. |
| Jan 28 | Dividend declaration | Neutral | -0.3% | Declared quarterly dividend of $0.50 per share with set record and pay dates. |
| Jan 22 | Fund distribution | Neutral | -3.3% | LGI fund announced monthly distribution with high return-of-capital component. |
Recent news and earnings generally saw price reactions aligned with the underlying news tone, with only one mild divergence on an AUM update.
Over the last month, Lazard has focused on financial performance, capital returns, and leadership. It reported Q4 and full-year 2025 results with full-year net revenue of $3,099M and record $1.8B adjusted Financial Advisory revenue, alongside AUM rising to $254B. A quarterly dividend of $0.50 per share was declared, and Tracy Farr was appointed CFO effective February 1, 2026. The January 2026 AUM update showed $266.95B, with net inflows and market gains. Today’s expansion of the Healthcare Services team fits this ongoing growth and leadership build-out narrative.
Market Pulse Summary
This announcement adds two senior Managing Directors to Lazard’s Healthcare Group, reinforcing its strategy of building sector-focused advisory depth in healthcare services. It follows recent milestones including record $1.8B adjusted Financial Advisory revenue in 2025, AUM of $266.95B as of January 2026, and a quarterly dividend of $0.50 per share. Investors may watch for subsequent transaction mandates, revenue contribution from healthcare, and any additional leadership or compensation disclosures in future earnings releases and 8-K filings.
AI-generated analysis. Not financial advice.
"John and Rob are exceptional advisors with deep sector expertise, a proven track record as thoughtful strategic advisors, and trusted client relationships," said David Gluckman, Global Head of Healthcare at Lazard. "Across the rapidly evolving healthcare services ecosystem, leadership teams, boards and investors face increasing complexity from evolving healthcare policy, dynamic macroeconomic and capital markets conditions, innovative payment models and technological transformation. The addition of John and Rob to our team will further enhance our ability to deliver high-impact, strategic and financial advice, helping our clients to seize opportunities and navigate this changing competitive landscape."
Prior to joining Lazard, John served as Managing Director at Allen & Co. where he advised healthcare companies across the healthcare services sector, including payors, providers, distributors, and companies at the intersection of healthcare and technology. Earlier in his career, he was a Resident in Orthopedic Surgery at the Hospital for Special Surgery. John holds an MBA from Harvard Business School, an MD from the Yale School of Medicine, and a BA in Biology from Harvard University.
"I am excited to join Lazard's Healthcare team, a platform known for its deep sector expertise and commitment to delivering thoughtful, high‑impact advice. The firm's entrepreneurial culture and global reach create a compelling opportunity to support clients as they navigate a rapidly evolving healthcare landscape," said John Koski.
Rob also joins Lazard from Allen & Co., where he was a Managing Director, advising on transactions across healthcare, including payors, providers, distributors, and companies at the intersection of healthcare and technology. Previously, Rob served as a Director in Healthcare at Citi as part of the Global Healthcare Investment Banking Group. He earned his MBA from NYU Stern and his bachelor's degree from Colgate University.
"Lazard's Healthcare franchise offers a unique combination of strategic insight, client focus, and a highly collaborative environment. I am thrilled to join this team and help build on its strong momentum, partnering with clients to capitalize on growth opportunities and address today's dynamic healthcare ecosystem," said Rob Lowe.
About Lazard
Founded in 1848, Lazard is the preeminent financial advisory and asset management firm, with operations in
Investor Relations
Alexandra Deignan
+1 212-632-6886
alexandra.deignan@lazard.com
Media Relations
Jessica Francisco
+1 212-632-6571
jessica.francisco@lazard.com
Shannon
+1 212-632-6880
shannon.houston@lazard.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/lazard-expands-its-healthcare-services-team-with-addition-of-john-koski-and-robert-lowe-302691391.html
SOURCE Lazard
FAQ
Who are John Koski and Rob Lowe and when did they join Lazard (LAZ)?
What experience do the new Lazard (LAZ) hires bring to the Healthcare Group?
How might the appointments of Koski and Lowe affect Lazard's (LAZ) healthcare advisory capabilities?
What are John Koski's academic and professional credentials noted by Lazard (LAZ)?
Where will Koski and Lowe be based and what sectors will they cover for Lazard (LAZ)?
